AstraZeneca PLC (AZN)
| Market Cap | 276.14B +31.1% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 26.58 |
| Forward PE | 16.78 |
| Dividend | $3.20 (1.80%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 1,974,670 |
| Open | 179.10 |
| Previous Close | 179.71 |
| Day's Range | 176.03 - 179.56 |
| 52-Week Range | 134.90 - 212.71 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 224.49 (+26.51%) |
| Earnings Date | Apr 29, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $224.49, which is an increase of 26.51% from the latest price.
News
AstraZeneca announces additional results from Phase III Serena-6 trial
Further positive results from the Phase III Serena-6 trial showed AstraZeneca’s (AZN) camizestrant plus a cyclin-dependent kinase, CDK, 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintai...
AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca’s (AZN) camizestrant plus a cyclin-dependent kinase 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintained it...
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
WILMINGTON, Del.--(BUSINESS WIRE)--Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib, riboci...
5 Foreign Stocks That Could Beat The S&P 500
James Demmert explains why foreign markets are beating the U.S.—and the five international stocks he thinks can outperform the S&P 500.
AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment
AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
Positive results from the EMERALD-3 Phase III trial showed AstraZeneca’s (AZN) Imfinzi in combination with Imjudo, lenvatinib and transarterial chemoembolization, TACE, demonstrated a statistically si...
AstraZeneca Scores In Liver Cancer On Its Path To $40 Billion In Oncology Sales
AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver cancer patients.
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transa...
AstraZeneca Transcript: Investor update
Significant pipeline progress includes new oncology approvals, robust phase III readouts, and strong commercial uptake. EMERALD-3 showed improved PFS with STRIDE+TACE, supporting practice change and blockbuster potential. Multiple innovative ADC, IO, and rare disease assets are advancing, with pivotal readouts and regulatory milestones expected soon.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
LUND, SE / ACCESS Newswire / June 1, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it w...
Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)
Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)
AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint
The company states: “The global CARES Phase 3 clinical programme showed that treatment with anselamimab, a potential first-in-class anti-fibril therapy, resulted in nominally statistically significant...
AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca Imfinzi combination approved in the U.S.
AstraZeneca’s (AZN) Imfinzi in combination with Bacillus Calmette-Guerin induction and maintenance therapy has been approved in the U.S. for the treatment of adult patients with BCG-naive, high-risk n...
FDA Approves IMFINZI Combination With BCG For Non-muscle-invasive Bladder Cancer In Adults
(RTTNews) - AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) announced that its IMFINZI (durvalumab), in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, has been approve...
AstraZeneca’s durvalumab approved in U.S. for NMIBC patients
The company states: “AstraZeneca’s (AZN) IMFINZI – or durvalumab – in combination with Bacillus Calmette-Guerin – BCG – induction and maintenance therapy has been approved in the US for the…
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatmen...
AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Gains FDA Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Gains FDA Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Secures U.S. Approval for Imfinzi Combination Therapy
AstraZeneca (AZN) Secures U.S. Approval for Imfinzi Combination Therapy
AstraZeneca confirms FDA approves Imfinzi combo for bladder cancer
AstraZeneca’s (AZN) Imfinzi in combination with Bacillus Calmette-Guerin induction and maintenance therapy has been approved in the U.S. for the treatment of adult patients with BCG-naive, high-risk n...
FDA approves durvalumab combo for high-risk non-muscle invasive bladder cancer
The Food and Drug Administration approved durvalumab, or Imfinzi, from AstraZeneca (AZN), in combination with Bacillus Calmette-Guerin for the treatment of adult patients with BCG-naive, high-risk non...
AZN's Patent Granted in Canada Strengthens Position in Male Infertility Treatment
AZN's Patent Granted in Canada Strengthens Position in Male Infertility Treatment
AstraZeneca (AZN) Receives FDA Extension for Drug Review
AstraZeneca (AZN) Receives FDA Extension for Drug Review